A five-year analysis of market share and sales growth for original drugs after patent expiration in Korea

Author:

Bae Minyoung1,Shim Sung Ryul2,Yang Dong-Wook1,Son Kyung-Bok3,Lee Sang-Won1

Affiliation:

1. Sungkyunkwan University

2. Konyang University

3. Hanyang University

Abstract

Abstract

Introduction: The sales patterns of original drugs after patent expiration in Korea differ from those in other countries. This study investigates how they differ. Methods: Using data from the Ministry of Food and Drug Safety, original drugs whose patents expired in 2012–2018 were divided into two groups depending on the generic drug approval. The differences in the attributes of each variable were analyzed. Additionally, we used IQVIA data to determine the market share and growth rate of 48 original drugs over five years from the launch of the first generic drug. Results: The average sales before the patent expiration of original drugs without a generic drug and the average sales before the first generic drug launch of original drugs with generic drugs were KRW 2.9 and 22.6 billion, respectively. The sales volume of off-patent original drugs in the fifth year had an average growth rate of 150.6% compared with that before the first generic drug launch, indicating a different trend from other countries. The average market share of off-patent original drugs in the same molecule market in the fifth year was 70.6%, which was higher than previously reported research results in Korea and other countries. Conclusion: This study analyzed the trend of original drugs’ sales volume, value, growth, and market share after the launch of a first generic drug. Furthermore, it demonstrated different patterns from those of other countries.

Publisher

Springer Science and Business Media LLC

Reference49 articles.

1. Current status and implications of foreign generic activation policies;Choi In Sun;KPBMA Brief,2019

2. Doctors News. https://www.doctorsnews.co.kr/news/articleView.html?idxno=127780

3. Medicopharma. https://blog.naver.com/medicopharma/222633523634

4. NEWSMP. http://www.newsmp.com/news/articleView.html?idxno=190383

5. NEWSMP. http://www.newsmp.com/news/articleView.html?idxno=203768

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3